Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00060476 | Treatment With MK0966 for the Prevention of Prostate Cancer (0966-201) | PHASE3 | COMPLETED | 15,000 | — | — | Jan 8, 2003 | Dec 8, 2004 | May 9, 2017 | - | — |
| Name | Type | Description |
|---|---|---|
| rofecoxib | DRUG | - |
| Comparator: placebo (unspecified) | DRUG | - |
Regular PSA testing and study biopsies required.